 TH1 cytokines, in conjunction with pharmacological AKT inhibition, potentiate apoptosis of breast cancer cells in vitro and suppress tumor growth in vivo. Over the years, numerous immunotherapy drugs have been developed, and additional research will aid in maximizing their therapeutic potential. In this top-performing paper published by Oncotarget in 2020, researchers used multiple human breast cancer cell lines to show that an AKT antagonist drug combined with two TH1 cytokines maximizes cell death and suppresses tumor growth. Read this study in more peer-reviewed oncology-focused research published by Oncotarget.